Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Luna, MS; Manzoni, P; Paes, B; Baraldi, E; Cossey, V; Kugelman, A; Chawla, R; Dotta, A; Rodríguez Fernández, R; Resch, B; Carbonell-Estrany, X.
Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.
Paediatr Respir Rev. 2020; 33(1-2):35-44
Doi: 10.1016/j.prrv.2018.12.001
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Resch Bernhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to cost-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. Almost 400 publications were reviewed. This group recommended palivizumab for: preterm infants (<29 and ≤31 weeks gestational age [wGA] and ≤9 and ≤6 months of age, respectively; high-risk 32-35wGA), former preterm children ≤24 months with chronic lung disease/bronchopulmonary dysplasia, children ≤24 months with significant congenital heart disease; and other high-risk populations, such as children ≤24 months with Down syndrome, pulmonary/neuromuscular disorders, immunocompromised, and cystic fibrosis. Up to 5 monthly doses should be administered over the RSV season. It is our impression that the adoption of these guidelines would help reduce the burden of RSV. Copyright © 2018 Elsevier Ltd. All rights reserved.
- Find related publications in this database (Keywords)
- Respiratory syncytial virus
- Evidence-based medicine
- Palivizumab
- Lower respiratory tract infection
- Neonatal lung disease